Big bottlenecks in cardiovascular tissue engineering

Although tissue engineering using human-induced pluripotent stem cells is a promising approach for treatment of cardiovascular diseases, some limiting factors include the survival, electrical integration, maturity, scalability, and immune response of three-dimensional (3D) engineered tissues. Here we discuss these important roadblocks facing the tissue engineering field and suggest potential approaches to overcome these challenges.In this Comment, Ngan Huang et al. discuss recent advances in cardiovascular tissue engineering and some of the main challenges that remain in translating these advances to the clinic. The authors propose future direction for the field to focus research efforts.

[1]  Laura E. Niklason,et al.  A short discourse on vascular tissue engineering , 2017, npj Regenerative Medicine.

[2]  Mark A. Skylar-Scott,et al.  Three-dimensional bioprinting of thick vascularized tissues , 2016, Proceedings of the National Academy of Sciences.

[3]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[4]  Udi Nussinovitch,et al.  Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker , 2016, Nature Biotechnology.

[5]  Katsushi Tokunaga,et al.  HLA-haplotype banking and iPS cells , 2008, Nature Biotechnology.

[6]  G. Fishman,et al.  Isolation and Characterization of ESC‐Derived Cardiac Purkinje Cells , 2014 .

[7]  Joseph C. Wu,et al.  Immunogenicity of Pluripotent Stem Cells and Their Derivatives , 2013, Circulation research.

[8]  K Rakusan,et al.  Morphometry of Human Coronary Capillaries During Normal Growth and the Effect of Age in Left Ventricular Pressure‐Overload Hypertrophy , 1992, Circulation.

[9]  Shinya Yamanaka,et al.  Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies , 2016, Regenerative therapy.

[10]  Milica Radisic,et al.  Distilling complexity to advance cardiac tissue engineering , 2016, Science Translational Medicine.

[11]  Deepak Srivastava,et al.  Multi-Imaging Method to Assay the Contractile Mechanical Output of Micropatterned Human iPSC-Derived Cardiac Myocytes , 2017, Circulation research.

[12]  Deepak Srivastava,et al.  Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness , 2015, Proceedings of the National Academy of Sciences.

[13]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[14]  Srivatsan Raghavan,et al.  Geometrically controlled endothelial tubulogenesis in micropatterned gels. , 2010, Tissue engineering. Part A.

[15]  Praveen Shukla,et al.  Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. , 2015, Stem cell research.

[16]  Charles E. Murry,et al.  Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate Non-Human Primate Hearts , 2014, Nature.

[17]  Milica Radisic,et al.  Medium perfusion enables engineering of compact and contractile cardiac tissue. , 2004, American journal of physiology. Heart and circulatory physiology.

[18]  Praveen Shukla,et al.  Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.

[19]  Gordana Vunjak-Novakovic,et al.  Advanced maturation of human cardiac tissue grown from pluripotent stem cells , 2018, Nature.

[20]  Jolanda van Hengel,et al.  Maturation of human pluripotent stem cell-derived cardiomyocytes , 2017 .

[21]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[22]  Lil Pabon,et al.  Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes , 2014, Circulation research.

[23]  Sebastian Michel,et al.  Heart transplantation: challenges facing the field. , 2014, Cold Spring Harbor perspectives in medicine.

[24]  Sean P. Palecek,et al.  Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions , 2012, Nature Protocols.

[25]  Molly M. Stevens,et al.  A conducting polymer with enhanced electronic stability applied in cardiac models , 2016, Science Advances.

[26]  Keiichi Fukuda,et al.  Efficient Large-Scale 2D Culture System for Human Induced Pluripotent Stem Cells and Differentiated Cardiomyocytes , 2017, Stem cell reports.

[27]  Bradley B. Keller,et al.  The myocardial regenerative potential of three-dimensional engineered cardiac tissues composed of multiple human iPS cell-derived cardiovascular cell lineages , 2016, Scientific Reports.

[28]  Milica Radisic,et al.  Engineered cardiac tissues. , 2011, Current opinion in biotechnology.

[29]  Ying Ge,et al.  Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. , 2014, Cell stem cell.

[30]  Teruo Okano,et al.  Bioengineered Myocardium Derived from Induced Pluripotent Stem Cells Improves Cardiac Function and Attenuates Cardiac Remodeling Following Chronic Myocardial Infarction in Rats , 2012, Stem cells translational medicine.

[31]  Ou Wang,et al.  Scalable and physiologically relevant microenvironments for human pluripotent stem cell expansion and differentiation , 2018, Biofabrication.

[32]  J. Vacanti,et al.  Tissue engineering : Frontiers in biotechnology , 1993 .

[33]  Pei-Rong Wang,et al.  HLA engineering of human pluripotent stem cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Ali Khademhosseini,et al.  Tough and flexible CNT-polymeric hybrid scaffolds for engineering cardiac constructs. , 2014, Biomaterials.

[35]  Hossein Baharvand,et al.  A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells , 2015, Stem cells translational medicine.

[36]  X. Rabasseda,et al.  A report from the American Heart Association Scientific Sessions 2012 (November 3-7 - Los Angeles, California, USA). , 2013, Drugs of today.

[37]  Ali Khademhosseini,et al.  Direct 3D bioprinting of perfusable vascular constructs using a blend bioink. , 2016, Biomaterials.

[38]  Sean P. Palecek,et al.  Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling , 2012, Proceedings of the National Academy of Sciences.

[39]  Eleonora Savio-Galimberti,et al.  Electrophysiologic Characterization of Calcium Handling in Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes , 2018, Stem cell reports.

[40]  Milica Radisic,et al.  Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires , 2017, Scientific Reports.

[41]  Bin Zhou,et al.  Epicardial FSTL1 reconstitution regenerates the adult mammalian heart , 2015, Nature.

[42]  Tal Dvir,et al.  Nanowired three dimensional cardiac patches , 2011, Nature nanotechnology.

[43]  Takashi Daimon,et al.  Feasibility, Safety, and Therapeutic Efficacy of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Sheets in a Porcine Ischemic Cardiomyopathy Model , 2012, Circulation.

[44]  Thomas Eschenhagen,et al.  Engineering Cardiac Muscle Tissue: A Maturating Field of Research. , 2017, Circulation research.

[45]  Pierre-Antoine Gourraud,et al.  The Role of Human Leukocyte Antigen Matching in the Development of Multiethnic “Haplobank” of Induced Pluripotent Stem Cell Lines , 2012, Stem cells.

[46]  Bradley B. Keller,et al.  Impact of Cell Composition and Geometry on Human Induced Pluripotent Stem Cells-Derived Engineered Cardiac Tissue , 2017, Scientific Reports.

[47]  Robert Langer,et al.  Three‐Dimensional Microfluidic Tissue‐Engineering Scaffolds Using a Flexible Biodegradable Polymer , 2006, Advanced materials.

[48]  Yihua Loo,et al.  Novel anisotropic engineered cardiac tissues: studies of electrical propagation. , 2007, Biochemical and biophysical research communications.